Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

6.175 +0.015 (+0.24%)
Streaming Delayed Price Updated: 9:37 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Savara, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? ↗
Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025. 
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April ↗
 
Via Benzinga
Topics Stocks
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
From Savara Inc.
Via Business Wire
News headline image
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.